Table 2.
Comparison of clinical parameters between patients with and without femoral abnormality on bone scintigraphy (n = 237)
| No femoral abnormality on bone scintigraphy (n = 226) | Femoral abnormality on bone scintigraphy (n = 11) | p value | |
|---|---|---|---|
| Age (years) | 0.229 | ||
| 73 (40 to 90) | 75 (58 to 86) | ||
| Sex | 0.346 | ||
| Female | 209 | 11 | |
| Male | 17 | 0 | |
| Medication route | 0.096 | ||
| Oral | 180 | 11 | |
| IV | 46 | 0 | |
| Disease | 0.393 | ||
| Osteoporosis | 193 | 11 | |
| Multiple myeloma | 15 | 0 | |
| Cancer | 18 | 0 | |
| BRONJ stage | 0.781 | ||
| 0 | 12 | 0 | |
| 1 | 8 | 0 | |
| 2 | 79 | 4 | |
| 3 | 127 | 7 | |
| Drug | 0.650 | ||
| Alendronate | 111 | 5 | |
| Ibandronate | 10 | 1 | |
| Pamidronate | 15 | 0 | |
| Risedronate | 37 | 3 | |
| Zoledronate | 23 | 0 | |
| Mixed | 30 | 2 | |
| BP duration (months) | 0.049 | ||
| 36 (3 to 156) | 60 (24 to 120) | ||
Data are presented as number of patients or median (range)
BRONJ bisphosphonate-related osteonecrosis of the jaw, IV intravenous, BP bisphosphonate